Rehabilitation Strategies for Social Participation in Chronic Stroke Survivors
Launched by UNIVERSITY OF PITTSBURGH · Jan 2, 2025
Trial Information
Current as of July 09, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new rehabilitation program designed to help people who have had a stroke return to social activities and live more independently in their communities. The program combines two approaches: strategy training and acceptance and commitment therapy (ST+ACT). Researchers want to see if people using this combined approach make more significant improvements in their social participation and flexibility in thinking, compared to those who only receive strategy training.
To participate, individuals must be at least 18 years old, have experienced a stroke at least six months prior, and currently live in the community but have difficulties with social activities. If eligible, participants will be assigned to either the ST+ACT program or the standard strategy training, each consisting of ten sessions conducted at home. They will undergo assessments before starting the program and again after the sessions and one month later to track their progress. This trial is not yet recruiting participants, but it aims to provide valuable insights into effective rehabilitation methods for stroke survivors.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. primary diagnosis of chronic stroke, ≥6 months post onset,
- • 2. ≥18 years old,
- • 3. community-dwelling (i.e., living in a residential setting in the community),
- • 4. restrictions in social participation, indicated by Activity Card Sort (\<80% of pre-stroke activities)
- Exclusion Criteria:
- • 1. progressive neurological diagnosis (e.g., dementia, Parkinson's disease, multiple sclerosis, or brain tumor) reported by participants or proxy,
- • 2. inability to provide written informed consent,
- • 3. severe aphasia (score 0 or 1 on the Boston Diagnostic Aphasia Examination 3rd Edition Severity Rating Scale),
- • 4. currently undergoing stroke rehabilitation or mental health intervention (but participation in maintenance sessions, self-help groups, or couples therapy is permitted),
- • 5. major depressive disorder, indicated by PRIME-MD, unless undergoing treatment for at least 4 weeks and are released to participate by their physician or counselor
- • 6. bipolar or psychotic disorder, indicated by PRIME-MD, or
- • 7. substance use disorder within 3 months, indicated by Mini-International Neuropsychiatric Interview
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Patients applied
Trial Officials
Minmei Shih, PhD
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported